Diabetic retinopathy (DR) is a major contributor to permanent vision loss and blindness. Changes in retinal neurons, glia, and microvasculature have been the focus of intensive study in the quest to better understand DR. However, the impact of diabetes on the rest of the visual system has received less attention. There are reports of associations of changes in the visual system with preclinical and clinical manifestations of diabetes. Simultaneous investigation of the retina and the brain may shed light on the mechanisms underlying neurodegeneration in diabetics. Additionally, investigating the links between DR and other neurodegenerative disorders of the brain including Alzheimer's and Parkinson's disease may reveal shared mechanisms for neurodegeneration and potential therapy options.
GuariguataL, et al.Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract2014; 103: 137–149.
2.
Collaboration, N.R.F. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants. The Lancet2016; 387: 1513–1530.
3.
OgurtsovaK, et al.IDF Diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract2017; 128: 40–50.
4.
MathersCDLoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med2006; 3: e442.
5.
LiZ, et al.Do microvascular changes occur preceding neural impairment in early-stage diabetic retinopathy? Evidence based on the optic nerve head using optical coherence tomography angiography. Acta Diabetol2019; 56: 1–9.
6.
ShinES, et al.High glucose alters retinal astrocytes phenotype through increased production of inflammatory cytokines and oxidative stress. PloS one2014; 9: e103148.
7.
SaaddineJB, et al.Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol2008; 126: 1740–1747.
8.
FerreiraFS, et al.Early visual cortical structural changes in diabetic patients without diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol2017; 255: 2113–2118.
9.
KimYKAnYParkSP. Intraocular and interocular differences in parafoveal vascular density in diabetic patients without diabetic retinopathy. Retina2021; 41: 170–180.
10.
WangZ-L, et al.Abnormal spontaneous brain activity in type 2 diabetic retinopathy revealed by amplitude of low-frequency fluctuations: a resting-state fMRI study. Clin Radiol2017; 72: 340. e1–340. e7.
11.
LeeSE, et al.Association between diabetic retinopathy and Parkinson disease: the Korean national health insurance service database. J Clin Endocrinol Metab2018; 103: 3231–3238.
12.
BorrelliE, et al.Impact of bleaching on photoreceptors in different intermediate AMD phenotypes. Transl Vis Sci Technol2019; 8: 5–5.
13.
YauJW, et al.Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care2012; 35: 556–564.
14.
FerreiraJT, et al.Retinal neurodegeneration in diabetic patients without diabetic retinopathy. Invest Ophthalmol Visual Sci2016; 57: 6455–6460.
15.
SimóR, et al.Neurovascular unit: a new target for treating early stages of diabetic retinopathy. Pharmaceutics2021; 13: 1320.
16.
PfisterF, et al.Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes2008; 57: 2495–2502.
17.
AntonettiDASilvaPSStittAW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol2021; 17: 195–206.
18.
RudrarajuMNarayananSPSomanathPR. Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res2020; 161: 105115.
19.
TonadeD, et al.Photoreceptor cells produce inflammatory products that contribute to retinal vascular permeability in a mouse model of diabetes. Diabetologia2017; 60: 2111–2120.
20.
LiuY, et al.TNF-α released from retinal Müller cells aggravates retinal pigment epithelium cell apoptosis by upregulating mitophagy during diabetic retinopathy. Biochem Biophys Res Commun2021; 561: 143–150.
21.
DuY, et al.Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci U S A2013; 110: 16586–16591.
22.
QuanY, et al.High glucose stimulates TNFα and MCP-1 expression in rat microglia via ROS and NF-κB pathways. Acta Pharmacol Sin2011; 32: 188–193.
23.
GarvinJ, et al.Astrocytic responses to high glucose impairs barrier formation in cerebral microvessel endothelial cells. Am J Physiol-Regul Integr Compar Physiol2022; 322: R571–R580.
24.
WangLLiuW-XHuangX-G. MicroRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3 K/AKT signalling pathway in an in vitro model of diabetic retinopathy. Exp Mol Pathol2020; 116: 104488.
25.
WangJ, et al.Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes2010; 59: 2297–2305.
26.
YunJ-H. Interleukin-1β induces pericyte apoptosis via the NF-κB pathway in diabetic retinopathy. Biochem Biophys Res Commun2021; 546: 46–53.
27.
SpencerBG, et al.Pericytes, inflammation, and diabetic retinopathy. Inflammopharmacology2020; 28: 697–709.
28.
CeciliaO-M, et al.Oxidative stress as the main target in diabetic retinopathy pathophysiology. J Diabetes Res2019; 2019: 8562408.
29.
GaseckaA, et al.Early biomarkers of neurodegenerative and neurovascular disorders in diabetes. J Clin Med2020; 9: 2807.
30.
AungMH, et al.Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes. J Neurosci2014; 34: 726–736.
31.
JenL, et al.Alzheimer’s peptide kills cells of retina in vivo. Nature1998; 392: 140–141.
32.
BitelCL, et al.Amyloid-β and tau pathology of Alzheimer’s disease induced by diabetes in a rabbit animal model. J Alzheimer’s Dis2012; 32: 291–305.
33.
ShuX, et al.Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling. Neuropharmacology2019; 153: 1–12.
34.
ZhuH, et al.GSK3β-mediated Tau hyperphosphorylation triggers diabetic retinal neurodegeneration by disrupting synaptic and mitochondrial functions. Mol Neurodegener2018; 13: 1–17.
35.
YunJ, et al.Angiopoietin 2 induces astrocyte apoptosis via αvβ5-integrin signaling in diabetic retinopathy. Cell Death Dis2016; 7: e2101–e2101.
36.
TamuraH, et al.Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Visual Sci2005; 46: 1440–1444.
37.
FernandezDC, et al.Early distal axonopathy of the visual pathway in experimental diabetes. Am J Pathol2012; 180: 303–313.
38.
BehlY, et al.Diabetes-enhanced tumor necrosis factor-α production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol2008; 172: 1411–1418.
39.
MandolesiG, et al.A role for retinal brain-derived neurotrophic factor in ocular dominance plasticity. Curr Biol2005; 15: 2119–2124.
40.
ZhangW, et al.Therapeutic efficacy of neural stem cells originating from umbilical cord-derived mesenchymal stem cells in diabetic retinopathy. Sci Rep2017; 7: 1–8.
41.
AfaridMNamvarESanie-JahromiF. Diabetic retinopathy and BDNF: a review on its molecular basis and clinical applications. J Ophthalmol2020; 2020: 1602739.
42.
Ino-ueM, et al.Polyol metabolism of retrograde axonal transport in diabetic rat large optic nerve fiber. Invest Ophthalmol Visual Sci2000; 41: 4055–4058.
43.
ZhangL, et al.Retrograde axonal transport impairment of large-and medium-sized retinal ganglion cells in diabetic rat. Curr Eye Res2000; 20: 131–136.
44.
CaoD, et al.Optic nerve head perfusion changes preceding peripapillary retinal nerve fibre layer thinning in preclinical diabetic retinopathy. Clin Exp Ophthalmol2019; 47: 219–225.
45.
ShibataM, et al.Involvement of glial cells in the autoregulation of optic nerve head blood flow in rabbits. Invest Ophthalmol Visual Sci2012; 53: 3726–3732.
46.
Velez-MontoyaR, et al.Acute onset central serous retinopathy in association with Mek inhibitor use for metastatic cancer. Invest Ophthalmol Visual Sci2011; 52: 2153–2153.
47.
SimardM, et al.Signaling at the gliovascular interface. J Neurosci2003; 23: 9254–9262.
48.
SofroniewMV. Astrocyte reactivity: subtypes, states, and functions in CNS innate immunity. Trends Immunol2020; 41: 758–770.
49.
YeZ-C, et al.Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci2003; 23: 3588–3596.
50.
EscartinC, et al.Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci2021; 24: 312–325.
51.
OthmanRVaucherECoutureR. Bradykinin type 1 receptor–inducible nitric oxide synthase: a new axis implicated in diabetic retinopathy. Front Pharmacol2019; 10: 300.
52.
CatanzaroOL, et al.Oxidative stress in the optic nerve and cortical visual area of steptozotocin-induced diabetic Wistar rats: blockade with a selective bradykinin B1 receptor antagonist. Neuropeptides2017; 66: 97–102.
53.
TongJ, et al.Brain metabolite alterations demonstrated by proton magnetic resonance spectroscopy in diabetic patients with retinopathy. Magn Reson Imaging2014; 32: 1037–1042.
54.
MoffettJR, et al.N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation. Front Neuroenergetics2013; 5: 11.
55.
PsomiadesM, et al.N-Acetyl-Aspartate in the dorsolateral prefrontal cortex in men with schizophrenia and auditory verbal hallucinations: a 1.5 T magnetic resonance spectroscopy study. Sci Rep2018; 8: 1–7.
56.
MathiesenHK, et al.Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol2006; 63: 533–536.
57.
LondonABenharISchwartzM. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol2013; 9: 44–53.
58.
SungMS, et al.Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson’s disease. Sci Rep2019; 9: 1–10.
59.
WangY, et al.Interplay of the norrin and Wnt7a/Wnt7b signaling systems in blood–brain barrier and blood–retina barrier development and maintenance. Proc Natl Acad Sci U S A2018; 115: E11827–E11836.
60.
MeteaMRNewmanEA. Signalling within the neurovascular unit in the mammalian retina. Exp Physiol2007; 92: 635–640.
61.
MengY, et al.Developmental whole brain white matter alterations in transgenic Huntington’s disease monkey. Sci Rep2017; 7: 1–12.
62.
YauY, et al.Network connectivity determines cortical thinning in early Parkinson’s disease progression. Nat Commun2018; 9: 1–10.
63.
GrimaldiA, et al.Neuroinflammatory processes, A1 astrocyte activation, and protein aggregation in the retina of Alzheimer’s disease patients, possible biomarkers for early diagnosis. Front Neurosci2019; 13: 925.
64.
HadouxX, et al.Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease. Nat Commun2019; 10: 1–12.
65.
JoeP, et al.A pilot study assessing retinal pathology in psychosis using optical coherence tomography: choroidal and macular thickness. Psychiatry Res2018; 263: 158–161.
66.
CheungCY-l, et al.Imaging retina to study dementia and stroke. Prog Retinal Eye Res2017; 57: 89–107.
67.
Pérez del PalomarA, et al.Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques. PloS one2019; 14: e0216410.
68.
CennamoG, et al.Anatomical and functional retinal changes in multiple sclerosis. Eye2016; 30: 456–462.
69.
BlokhuisC, et al.The eye as a window to the brain: neuroretinal thickness is associated with microstructural white matter injury in HIV-infected children. Invest Ophthalmol Visual Sci2016; 57: 3864–3871.
70.
SarmaMK, et al.Regional brain gray and white matter changes in perinatally HIV-infected adolescents. NeuroImage: Clin2014; 4: 29–34.
71.
RagauskasS, et al.Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington’s disease. PLoS One2014; 9: e113317.
72.
OgawaS, et al.White matter consequences of retinal receptor and ganglion cell damage. Invest Ophthalmol Visual Sci2014; 55: 6976–6986.
73.
HuangX, et al.Disrupted topological organization of human brain connectome in diabetic retinopathy patients. Neuropsychiatr Dis Treat2019; 15: 2487–2502.
74.
PlankT, et al.Gray matter alterations in visual cortex of patients with loss of central vision due to hereditary retinal dystrophies. Neuroimage2011; 56: 1556–1565.
75.
DanH-D, et al.Altered intra-and inter-regional functional connectivity of the visual cortex in individuals with peripheral vision loss due to retinitis pigmentosa. Vision Res2019; 159: 68–75.
76.
HugenschmidtCE, et al.The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care2014; 37: 3244–3252.
77.
GuptaP, et al.Association between diabetic retinopathy and incident cognitive impairment. Br J Ophthalmol2019; 103: 1605–1609.
78.
TrentoM, et al.Cognitive function may be a predictor of retinopathy progression in patients with type 2 diabetes. Eur J Ophthalmol2017; 27: 278–280.
79.
XiaS-S, et al.The factors contributing to cognitive dysfunction in type 2 diabetic patients. Ann Transl Med2020; 8: 104.
80.
SundstromJM, et al.Proteomic analysis of early diabetic retinopathy reveals mediators of neurodegenerative brain diseases. Invest Ophthalmol Visual Sci2018; 59: 2264–2274.
81.
LiebschF, et al.Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression. Nat Commun2019; 10: 1–15.
82.
MoranC, et al.The association of Type 2 diabetes mellitus with cerebral gray matter volume is independent of retinal vascular architecture and retinopathy. J Diabetes Res2016; 2016: 6328953.
83.
JoelvingF, et al.Hippocampal neuron and glial cell numbers in Parkinson's disease—a stereological study. Hippocampus2006; 16: 826–833.
84.
KulkarniVAFiresteinBL. The dendritic tree and brain disorders. Mol Cell Neurosci2012; 50: 10–20.
85.
MurphyDG, et al.Sex differences in human brain morphometry and metabolism: an in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging. Arch Gen Psychiatry1996; 53: 585–594.
86.
YuY, et al.Intrinsic functional connectivity alterations of the primary visual cortex in patients with proliferative diabetic retinopathy: a seed-based resting-state fMRI study. Ther Adv Endocrinol Metab2020; 11: 2042018820960296.
87.
SabelBAGaoYAntalA. Reversibility of visual field defects through induction of brain plasticity: vision restoration, recovery and rehabilitation using alternating current stimulation. Neural Regen Res2020; 15: 1799.
88.
KüblböckM, et al.Stability of low-frequency fluctuation amplitudes in prolonged resting-state fMRI. Neuroimage2014; 103: 249–257.
89.
ChangM, et al.Spontaneous low-frequency fluctuations in the neural system for emotional perception in major psychiatric disorders: amplitude similarities and differences across frequency bands. J Psychiatry Neurosci2019; 44: 132–141.
90.
WangP, et al.Amplitude of low-frequency fluctuation (ALFF) may be associated with cognitive impairment in schizophrenia: a correlation study. BMC Psychiatry2019; 19: 30.
91.
WangJ, et al.Consistent decreased activity in the putamen in Parkinson's disease: a meta-analysis and an independent validation of resting-state fMRI. GigaScience2018; 7: giy071.
92.
AnL, et al.Local synchronization and amplitude of the fluctuation of spontaneous brain activity in attention-deficit/hyperactivity disorder: a resting-state fMRI study. Neurosci Bull2013; 29: 603–613.
93.
ZhaoZ, et al.Selective changes of resting-state brain oscillations in aMCI: an fMRI study using ALFF. 2014; 2014: 920902.
94.
WangY, et al.The predictive potential of altered spontaneous brain activity patterns in diabetic retinopathy and nephropathy. EPMA J2019; 10: 249–259.
95.
QiC-XHuangXShenY. Altered intrinsic brain activities in patients with diabetic retinopathy using amplitude of low-frequency fluctuation: a resting-state fMRI study. Diabetes, Metab Syndr Obes: Targets Ther2020; 13: 2833.
96.
BuL, et al.Alteration in brain functional and effective connectivity in subjects with hypertension. Front Physiol2018; 9: 669.
97.
KitajimaM, et al.MR Changes in the calcarine area resulting from retinal degeneration. Am J Neuroradiol1997; 18: 1291–1295.
98.
GutniskyDA, et al.Spontaneous fluctuations in visual cortical responses influence population coding accuracy. Cereb CORtex2017; 27: 1409–1427.
99.
CunninghamSI, et al.Feasibility of structural and functional MRI acquisition with unpowered implants in Argus II retinal prosthesis patients: a case study. Transl Vis Sci Technol2015; 4: 6–6.
100.
WesselsA, et al.Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia2006; 49: 2474–2480.
101.
SohnEH, et al.Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci U S A2016; 113: E2655–E2664.
102.
XiaZChenH. Alterations of retinal pigment epithelium-photoreceptor complex in patients with type 2 diabetes mellitus without diabetic retinopathy: a cross-sectional study. 2020; 2020: 9232157.
103.
ZhangY, et al.Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation. Transl Psychiatry2016; 6: e982–e982.
104.
BernardesG, et al.Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin. Metab Brain Dis2018; 33: 1211–1222.
105.
MooradianAD. Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol2009; 5: 150–159.
106.
HuangX, et al.Large-scale neuronal network dysfunction in diabetic retinopathy. Neural Plast2020; 2020: 6872508.
107.
BullmoreESpornsO. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci2009; 10: 186–198.
108.
WangMY, et al.Neuroticism and conscientiousness respectively positively and negatively correlated with the network characteristic path length in dorsal lateral prefrontal cortex: a resting-state fNIRS study. Brain Behav2018; 8: e01074.
109.
DaiH, et al.Brain functional networks: correlation analysis with clinical indexes in patients with diabetic retinopathy. Neuroradiology2017; 59: 1121–1131.
110.
RichardsTL, et al.Brain’s functional network clustering coefficient changes in response to instruction (RTI) in students with and without reading disabilities: multi-leveled reading brain’s RTI. Cogent Psychol2018; 5: 1424680.
111.
HuiF, et al.Retinal and cortical blood flow dynamics following systemic blood-neural barrier disruption. Front Neurosci2017; 11: 568.
112.
ZhangL, et al.Upregulation of CKIP-1 inhibits high-glucose induced inflammation and oxidative stress in HRECs and attenuates diabetic retinopathy by modulating Nrf2/ARE signaling pathway: an in vitro study. Cell Biosci2019; 9: 1–12.
113.
XieY, et al.MicroRNA-146a: a comprehensive indicator of inflammation and oxidative stress status induced in the brain of chronic T2DM rats. Front Pharmacol2018; 9: 478.
114.
BossJD, et al.Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Visual Sci2017; 58: 5594–5603.
115.
OkuH, et al.Tau is involved in death of retinal ganglion cells of rats from optic nerve crush. Invest Ophthalmol Visual Sci2019; 60: 2380–2387.
116.
ChiasseuM, et al.Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer’s disease. Mol Neurodegener2017; 12: 1–20.
117.
ZhouM, et al.Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β. Biochem Biophys Res Commun2019; 511: 154–160.
118.
YingY, et al.Neuroprotective effects of ginsenoside Rg1 against hyperphosphorylated tau-induced diabetic retinal neurodegeneration via activation of IRS-1/Akt/GSK3β signaling. J Agric Food Chem2019; 67: 8348–8360.
119.
LatinaV, et al.Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s disease. Acta Neuropathol Commun2021; 9: 1–27.
120.
PlanelE, et al.Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci2007; 27: 13635–13648.
121.
Rodriguez-RodriguezP, et al.Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. Brain2017; 140: 3269–3285.
122.
WangT, et al.Involvement of insulin signaling disturbances in bisphenol A-induced Alzheimer’s disease-like neurotoxicity. Sci Rep2017; 7: 7497.
123.
GrilloC, et al.Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res2009; 1296: 35–45.
124.
Pearson-LearyJMcNayEC. Novel roles for the insulin-regulated glucose transporter-4 in hippocampally dependent memory. J Neurosci2016; 36: 11851–11864.
125.
RheaEMBanksWA. Role of the blood-brain barrier in central nervous system insulin resistance. Front Neurosci2019; 13: 521.
126.
KellarD, et al.Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial. Sci Rep2022; 12: 1–11.
127.
GuoZ, et al.Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model. Sci Rep2017; 7: 1–12.
128.
SchererTSakamotoKBuettnerC. Brain insulin signalling in metabolic homeostasis and disease. Nat Rev Endocrinol2021; 17: 468–483.
129.
RajalaA, et al.Loss of neuroprotective survival signal in mice lacking insulin receptor gene in rod photoreceptor cells. J Biol Chem2008; 283: 19781–19792.
130.
FoxTE, et al.Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes2006; 55: 3573–3580.
131.
WalkerRJ, et al.Silencing of insulin receptor substrate–1 increases cell death in retinal Müller cells. Mol Vision2012; 18: 271.
132.
OlaMSHosoyaK-ILaNoueKF. Influence of insulin on glutamine synthetase in the Müller glial cells of retina. Metab Brain Dis2011; 26: 195–202.
133.
JiangY, et al.Insulin signal transduction is impaired in the type 2 diabetic retina. J Diabetes Clin Res2020; 2: 12.
134.
TarchickMJ, et al.Endogenous insulin signaling in the RPE contributes to the maintenance of rod photoreceptor function in diabetes. Exp Eye Res2019; 180: 63–74.
135.
ReiterCE, et al.Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes2006; 55: 1148–1156.
136.
ImaiH, et al.Subconjunctivally implanted hydrogels for sustained insulin release to reduce retinal cell apoptosis in diabetic rats. Invest Ophthalmol Visual Sci2015; 56: 7839–7846.
137.
JiangYZhangQSteinleJJ. Intravitreal injection of IGFBP-3 restores normal insulin signaling in diabetic rat retina. PLoS One2014; 9: e93788.
138.
WarmkeN, et al.Pericyte insulin receptors modulate retinal vascular remodeling and endothelial angiopoietin signaling. Endocrinology2021; 162: bqab182.
139.
AbuhaibaSI, et al.Occipital blood-brain barrier permeability is an independent predictor of visual outcome in type 2 diabetes, irrespective of the retinal barrier: A longitudinal study. Journal of Neuroendocrinology2018; 30: e12566.
140.
BogushMHeldtNAPersidskyY. Blood brain barrier injury in diabetes: unrecognized effects on brain and cognition. J Neuroimmune Pharmacol2017; 12: 593–601.
141.
SheikhMH, et al.Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: therapeutic avenues. 2022; 36: e22107.
142.
NationDA, et al.Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med2019; 25: 270–276.
143.
SengilloJD, et al.Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer’s disease. Brain Pathol2013; 23: 303–310.
144.
WilcockDMVitekMPColtonCA. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer’s disease. Neuroscience2009; 159: 1055–1069.
145.
LepelletierFX, et al.Early changes in extracellular matrix in Alzheimer’s disease. Neuropathol Appl Neurobiol2017; 43: 167–182.
146.
ChronopoulosA, et al.High glucose-induced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr Eye Res2011; 36: 747–753.
147.
HammesHP, et al.Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes2004; 53: 1104–1110.
148.
LyA, et al.Early inner retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress, and neuronal functional loss. Invest Ophthalmol Vis Sci2011; 52: 9316–9326.
149.
SehgalP, et al.LncRNA VEAL2 regulates PRKCB2 to modulate endothelial permeability in diabetic retinopathy. 2021; 40: e107134.
150.
AcharyaNK, et al.Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis2013; 35: 179–198.
151.
GoldwaserEL, et al.Breakdown of the cerebrovasculature and blood-brain barrier: a mechanistic link between diabetes mellitus and Alzheimer’s disease. J Alzheimers Dis2016; 54: 445–456.
152.
ChenJ, et al.FGF21 Protects the blood-brain barrier by upregulating PPARγ via FGFR1/β-klotho after traumatic brain injury. J Neurotrauma2018; 35: 2091–2103.
153.
BrownRC, et al.Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium. Am J Physiol Cell Physiol2004; 286: C1045–C1052.
154.
KawoosU, et al.N-acetylcysteine amide ameliorates blast-induced changes in blood-brain barrier integrity in rats. Front Neurol2019; 10: 650.
155.
EricksonMAHansenKBanksWA. Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine. Brain Behav Immun2012; 26: 1085–1094.
156.
MattssonN, et al.Staging β-amyloid pathology with amyloid positron emission tomography. JAMA Neurol2019; 76: 1319–1329.
157.
LiuLP, et al.Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Acta Pharmacol Sin2013; 34: 455–463.
158.
YonedaS, et al.Vitreous fluid levels of beta-amyloid((1–42)) and tau in patients with retinal diseases. Jpn J Ophthalmol2005; 49: 106–108.
159.
BitelCL, et al.Amyloid-β and tau pathology of Alzheimer’s disease induced by diabetes in a rabbit animal model. J Alzheimers Dis2012; 32: 291–305.
160.
HowlettDR, et al.Characterisation of amyloid-induced inflammatory responses in the rat retina. Exp Brain Res2011; 214: 185–197.
161.
ShimazawaM, et al.Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. J Neurochem2008; 107: 279–290.
TalantovaM, et al.Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A2013; 110: E2518–E2527.
164.
DongH, et al.Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer’s disease. Neuropsychopharmacology2008; 33: 3226–3236.
165.
NagayachAPatroNPatroI. Experimentally induced diabetes causes glial activation, glutamate toxicity and cellular damage leading to changes in motor function. Front Cell Neurosci2014; 8: 355.
166.
UedaD, et al.Neuropeptide Y and glutamatergic mechanisms in the amygdala and ventral hippocampus differentially mediate impaired social behavior in diabetic mice. Behav Brain Res2021; 405: 113195.
167.
KusariJ, et al.Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci2007; 48: 5152–5159.
168.
NeekhraA, et al.Memantine, simvastatin, and epicatechin inhibit 7-ketocholesterol-induced apoptosis in retinal pigment epithelial cells but not neurosensory retinal cells in vitro. J Ophthalmic Vis Res2020; 15: 470–480.
169.
AtlaszT, et al.Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann N Y Acad Sci2010; 1200: 128–139.
170.
MugishoOO, et al.Bradykinin receptor-1 activation induces inflammation and increases the permeability of human brain microvascular endothelial cells. Cell Biol Int2019; 44: 343–351.
171.
OthmanRVaucherECoutureR. Bradykinin type 1 receptor – inducible nitric oxide synthase: a new axis implicated in diabetic retinopathy. Front Pharmacol2019; 10: 300.
172.
CatanzaroOL, et al.Oxidative stress in the optic nerve and cortical visual area of steptozotocin-induced diabetic Wistar rats: blockade with a selective bradykinin B(1) receptor antagonist. Neuropeptides2017; 66: 97–102.
173.
AsrafK, et al.Involvement of the bradykinin B(1) receptor in microglial activation: in vitro and in vivo studies. Front Endocrinol (Lausanne)2017; 8: 82.
174.
BarićADobrivojević RadmilovićM. Microglia and bradykinin cross talk in poststroke cognitive impairment in diabetes. Am J Physiol Cell Physiol2021; 320: C613–c618.
175.
HernándezC, et al.Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes2013; 62: 2569–2578.
176.
WeirKKimDWBlackshawS. A potential role for somatostatin signaling in regulating retinal neurogenesis. Sci Rep2021; 11: 10962.
177.
SongYHYoonJLeeSH. The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders. 2021; 53: 328–338.
178.
CarrascoE, et al.Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care2007; 30: 2902–2908.
179.
HernándezC, et al.Effect of topical administration of somatostatin on retinal inflammation and neurodegeneration in an experimental model of diabetes. 2020; 9.
180.
BeltramoE, et al.Effects of the neuroprotective drugs somatostatin and brimonidine on retinal cell models of diabetic retinopathy. Acta Diabetol2016; 53: 957–964.
181.
XiaoMingZ, et al.Specific changes of somatostatin mRNA expression in the frontal cortex and hippocampus of diabetic rats. J Anat2004; 204: 221–225.
182.
JiaoSS, et al.Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Transl Psychiatry2016; 6: e907.
183.
Miranda-LourençoC, et al.Challenges of BDNF-based therapies: from common to rare diseases. Pharmacol Res2020; 162: 105281.
184.
KrabbeKS, et al.Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia2007; 50: 431–438.
185.
ThubronEB, et al.Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease. 2019; 9: 11386.
186.
PoeweW, et al.Parkinson Disease. Nat Rev Dis Primers2017; 3: 17013.
187.
TianTLiZLuH. Common pathophysiology affecting diabetic retinopathy and Parkinson’s disease. Med Hypotheses2015; 85: 397–398.
188.
ZhangJ, et al.Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol1999; 154: 1423–1429.
189.
CalderonG, et al.Oxidative stress and diabetic retinopathy: development and treatment. Eye2017; 31: 1122–1130.
190.
WangX, et al.DLP1-dependent Mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson’s disease. Aging Cell2011; 10: 807–823.
191.
YangHS, et al.Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in Korean patients with type 2 diabetes mellitus. Invest Ophthalmol Visual Sci2014; 55: 5989–5997.
192.
HongC-T, et al.Insulin resistance promotes Parkinson’s disease through aberrant expression of α-synuclein, mitochondrial dysfunction, and deregulation of the polo-like kinase 2 signaling. Cells2020; 9: 740.
193.
HenchcliffeCBealMF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol2008; 4: 600–609.
194.
CerettaLB, et al.Increased oxidative stress and imbalance in antioxidant enzymes in the brains of alloxan-induced diabetic rats. Exp Diabetes Res2012; 2012: 302682.
195.
Aviles-OlmosI, et al.Parkinson’s disease, insulin resistance and novel agents of neuroprotection. Brain2013; 136: 374–384.
196.
Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol2015; 14: 795–803.
197.
ZhaoT, et al.Upregulating microRNA-498 inhibits gastric cancer proliferation invasion and chemoresistance through inverse interaction of Bmi1. Cancer Gene Ther2018.
198.
Aviles-OlmosI, et al.Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest2013; 123: 2730–2736.
199.
BrauerR, et al.Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes. Brain2020; 143: 3067–3076.
200.
PouliotM, et al.Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. PloS one2012; 7: e33864.
201.
AbdouhM, et al.Early upregulation of kinin B1 receptors in retinal microvessels of the streptozotocin-diabetic rat. Br J Pharmacol2003; 140: 33–40.
202.
HachanaS, et al.Expression, distribution and function of kinin B1 receptor in the rat diabetic retina. Br J Pharmacol2018; 175: 968–983.
203.
Niewiarowska-SendoAKozikAGuevara-LoraI. Kinin peptides enhance inflammatory and oxidative responses promoting apoptosis in a Parkinson’s disease cellular model. 2016; 2016: 4567343.
204.
BorlonganCV, et al.Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. Brain Res2002; 956: 211–220.
205.
HernándezCSimó-ServatOSimóR. Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine2014; 46: 209–214.
206.
Sánchez-GómezA, et al.Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: a population-based cohort study. Parkinsonism Relat Disord2021; 89: 22–27.
